INNOVATE Q3 rev $375M (-11% YoY), Adj EBITDA $22.1M (+35%); extends note maturity to 2025

INNOVATE Corp.

2023-Q3 EPS reported -$0.36 revenue$1,062,000,000

Net loss $7.3M ($0.09/sh) flat YoY; Adj EBITDA $22.1M vs $16.4M (+34.8%).
Infrastructure DBM Global rev $369.3M (-10.5%), Adj EBITDA margin 8.3% (+170bps), backlog $1.3B.
Spectrum rev $5.4M (-41%) due to Azteca closure; exploring datacasting partnerships with HPE and PBS.
Life Sciences rev $0.6M, loss narrows; MediBeacon continues FDA approval process.
Post-quarter: extended $69.7M secured notes maturity to Aug 2025; INNOVATE to use sale proceeds for repayment.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INNOVATE Corp. reported third quarter 2023 results: revenue $375.3 million, net income Net loss attributable to common stockholders of $7.3 million, EPS $0.09 per fully diluted share.

Period: third quarter 2023
Revenue: $375.3 million
Net income: Net loss attributable to common stockholders of $7.3 million
EPS: $0.09 per fully diluted share
Result: reported results

Exact text from the filing

Adjusted EBITDA (1) $ 22.1 $ 16.4 34.8 % $ 43.5 $ 40.0 8.7 % (1) Reconciliation of GAAP to Non-GAAP measures follows Commentary “INNOVATE delivered third quarter revenue of $375.3 million and experienced strong Adjusted EBITDA growth of 34.8%, which was primarily driven by our Infrastructure and Life Sciences operating segments," said Avie Glazer, Chairman of

View on SEC.gov

Browse all earnings releases →

INNOVATE Corp. filing history →

Source: SEC EDGAR

accession 0001006837-23-000127

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.